PMID: identifiant
de la référence Pubmed : |
 |
 (23129208)  |
|
| titre : |
|
Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials. |
|
| auteur(s) : |
|
François-Clément Bidard ( ) 1, 2, Tanja Fehm3, Michail Ignatiadis4, Jeffrey Smerage5, Catherine Alix-Panabières6, Wolfgang Janni7, Carlo Messina8, Costanza Paoletti5, Volkmar Müller9, Daniel Hayes5, Martine Piccart4, Jean-Yves Pierga1 |
|
| laboratoire : |
|
| 1 : |
Service d'Oncologie Médicale |
|
| Institut Curie |
|
| 26 rue d'Ulm, 75005 Paris |
|
| France |
|
| 2 : |
UP5 - Université Paris 5, Paris Descartes |
|
| http://www.univ-paris5.fr/ |
|
| Université Paris V - Paris Descartes – Ministère de l'Enseignement Supérieur et de la Recherche Scientifique |
|
| 12, rue de l'École de Médecine - 75270 Paris cedex 06 |
|
| France |
|
| 3 : |
Department of Gynecology and Obstetrics |
|
| University of Tubingen |
|
| Calwer Strasse 7, 72076 Tübingen |
|
| Allemagne |
|
| 4 : |
Department of medical oncology |
|
| Institut Jules Bordet |
|
| Brussels |
|
| Belgique |
|
| 5 : |
Breast Oncology Program |
|
| University of Michigan |
|
| Comprehensive Cancer Center, Ann Arbor, Michigan |
|
| États-Unis |
|
| 6 : |
Laboratoire cellules circulantes rares humaines |
|
| CHRU Montpellier – Hôpital Saint-Eloi |
|
| Institut de recherche en biothérapie, 80 avenue Augustin Fliche, F-34295 Montpellier Cedex 5 |
|
| France |
|
| 7 : |
Department of Gynecology and Obstetrics |
|
| University of Dusseldorf |
|
| Moorenstrasse 5, 40225 Düsseldorf |
|
| Allemagne |
|
| 8 : |
EORTC - European Organization for Research and Treatment of Cancer |
|
| EORTC |
|
| Headquarters, Brussels |
|
| Belgique |
|
| 9 : |
Department of Gynecology |
|
| University Medical Center Hamburg-Eppendorf |
|
| Hamburg |
|
| Allemagne |
|
|
| résumé : |
|
In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients. |
|
| domaine : |
|
Sciences du Vivant/Cancérologie
|
|
langue du texte
intégral : |
|
Anglais |
|
| ISSN : |
|
0167-7659 |
|
|
| type de publication : |
|
Articles dans des revues avec comité de lecture |
|
| DOI : |
|
10.1007/s10555-012-9398-0 |
|
| journal : |
|
| Cancer and Metastasis Reviews (Cancer Metastasis Rev) |
| Publisher |
Springer Verlag (Germany) |
| ISSN |
0167-7659 (eISSN : 1573-7233) |
|
|
| Audience : |
|
internationale |
|
| date de publication : |
|
06/11/2012 |
|
date de publication
électronique : |
|
06/11/2012 |
|
| page, identifiant, ... : |
|
epub ahead of print |
|
|
| mots-clés auteur : |
|
cellules tumorales circulantes – circulating tumor cells – breast cancer – cancer du sein – CTC – STIC CTC – CirCe01 – CirCe 01 – ETI score – STIC CTC METABREAST – Detect III – TREAT CTC – CirCe XXX1 – CirCeXXX1 – CirCe T-DM1 – CirCeT-DM1 – phase III trials. |
|
| contrat, financement : |
|
The CirCe01 trial has been funded / supported by La Ligue Contre Le Cancer (#20%), the French ministry of Health (#60%) and Veridex (#20%). The promoter is the Institut Curie. |
|
